Understanding Cannabis Addiction: Mechanisms, Withdrawal, and Treatment Targets
A comprehensive review of cannabinoid abuse mechanisms found that while no approved medications exist for cannabis use disorder, several molecular targets including FAAH inhibitors and allosteric CB1 modulators show promise in preclinical models.
Quick Facts
What This Study Found
This review synthesized research on the mechanisms of cannabinoid abuse, withdrawal, and relapse from both human and animal studies.
The review described how cannabinoids produce rewarding effects through CB1 receptor activation in the brain's reward circuitry, how tolerance develops through receptor downregulation, and how withdrawal symptoms emerge when chronic stimulation stops. Cannabis withdrawal includes irritability, anxiety, sleep disturbance, and decreased appetite.
Several potential pharmacotherapy targets were identified: FAAH inhibitors (which boost endocannabinoid levels), allosteric modulators of CB1 receptors, and medications targeting overlapping neurotransmitter systems. However, no approved treatments existed at the time of publication.
Key Numbers
No approved medications for cannabis use disorder; potential targets reviewed: FAAH inhibitors, allosteric CB1 modulators, GABAergic agents, and others
How They Did This
Comprehensive review of preclinical and clinical research on cannabinoid abuse, covering reward mechanisms, adverse effects, withdrawal, relapse, and potential pharmacotherapies.
Why This Research Matters
Cannabis use disorder affects millions of people worldwide, yet there are no FDA-approved medications for treatment. Understanding the neurobiology of cannabis addiction is essential for developing targeted treatments.
The Bigger Picture
As cannabis potency increases and access expands, the number of people developing cannabis use disorder is likely to grow. The development of effective pharmacotherapies is increasingly urgent.
What This Study Doesn't Tell Us
Many promising pharmacological targets had only preclinical support at the time. Animal models of cannabis reward and relapse may not fully capture human addiction. The review acknowledged that most candidate medications face significant development hurdles.
Questions This Raises
- ?Which pharmacological targets will prove most effective in human clinical trials?
- ?Can combination therapies improve outcomes?
- ?Would different medications work better for different aspects of cannabis addiction (withdrawal vs. craving vs. relapse)?
Trust & Context
- Key Stat:
- Zero approved medications for cannabis use disorder as of 2015
- Evidence Grade:
- Comprehensive review in a major pharmacology journal, synthesizing human and animal research. Individual treatment targets had varying levels of evidence.
- Study Age:
- Published in 2015. Several clinical trials of potential cannabis addiction medications have since been conducted.
- Original Title:
- Cannabinoid abuse and addiction: Clinical and preclinical findings.
- Published In:
- Clinical pharmacology and therapeutics, 97(6), 616-27 (2015)
- Authors:
- Panlilio, L V, Goldberg, S R, Justinova, Z
- Database ID:
- RTHC-01033
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can you get addicted to cannabis?
Yes. Cannabis use disorder is a recognized clinical condition. This review described the neurobiological mechanisms: CB1 receptor activation in reward circuits, tolerance through receptor changes, and withdrawal symptoms when chronic use stops.
Are there medications for cannabis addiction?
As of this 2015 review, no medications were approved for cannabis use disorder. Several targets showed promise in preclinical research, including FAAH inhibitors and CB1 receptor modulators, but none had completed clinical development.
Read More on RethinkTHC
- 30-days-without-weed
- 6-months-sober-weed-what-to-expect
- 90-days-no-weed
- benefits-of-quitting-weed
- boredom-after-quitting-weed
- boredom-after-quitting-weed-nothing-fun
- cannabis-dependence-physical-psychological-addiction-science
- cannabis-perception-vs-evidence-gap
- cannabis-use-disorder-test
- creativity-without-weed-quitting-artist-musician
- cross-addiction-quit-weed-start-drinking
- hobbies-after-quitting-weed
- identity-after-quitting-weed
- is-weed-addictive
- is-weed-addictive-science
- leaving-stoner-culture-identity
- money-saved-quitting-weed-calculator
- one-year-sober-weed
- quitting-weed-and-alcohol
- quitting-weed-creativity
- quitting-weed-face-changes-skin
- quitting-weed-weight-loss-gain
- rehab-for-weed-addiction-necessary
- signs-of-cannabis-use-disorder
- weed-vape-pen-addiction
Cite This Study
https://rethinkthc.com/research/RTHC-01033APA
Panlilio, L V; Goldberg, S R; Justinova, Z. (2015). Cannabinoid abuse and addiction: Clinical and preclinical findings.. Clinical pharmacology and therapeutics, 97(6), 616-27. https://doi.org/10.1002/cpt.118
MLA
Panlilio, L V, et al. "Cannabinoid abuse and addiction: Clinical and preclinical findings.." Clinical pharmacology and therapeutics, 2015. https://doi.org/10.1002/cpt.118
RethinkTHC
RethinkTHC Research Database. "Cannabinoid abuse and addiction: Clinical and preclinical fi..." RTHC-01033. Retrieved from https://rethinkthc.com/research/panlilio-2015-cannabinoid-abuse-and-addiction
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.